Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| adipocyte | 9 studies | 41% ± 14% | |
| hepatocyte | 4 studies | 46% ± 23% | |
| glutamatergic neuron | 4 studies | 32% ± 9% | |
| epithelial cell | 3 studies | 18% ± 3% | |
| GABAergic neuron | 3 studies | 35% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 4 studies | 25% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 3737.21 | 226 / 226 | 100% | 82.52 | 404 / 406 |
| kidney | 100% | 1400.30 | 89 / 89 | 99% | 36.63 | 890 / 901 |
| brain | 98% | 306.04 | 2587 / 2642 | 99% | 11.64 | 697 / 705 |
| ovary | 99% | 366.45 | 179 / 180 | 97% | 11.99 | 418 / 430 |
| thymus | 100% | 705.92 | 653 / 653 | 96% | 29.82 | 582 / 605 |
| breast | 99% | 1056.74 | 456 / 459 | 93% | 11.49 | 1042 / 1118 |
| adrenal gland | 98% | 495.88 | 253 / 258 | 92% | 10.51 | 212 / 230 |
| prostate | 98% | 336.84 | 241 / 245 | 89% | 8.77 | 449 / 502 |
| intestine | 100% | 552.46 | 963 / 966 | 88% | 10.35 | 463 / 527 |
| stomach | 97% | 249.49 | 347 / 359 | 91% | 9.84 | 259 / 286 |
| lung | 98% | 423.60 | 566 / 578 | 89% | 9.54 | 1027 / 1155 |
| pancreas | 91% | 204.29 | 298 / 328 | 94% | 15.06 | 168 / 178 |
| uterus | 98% | 301.98 | 167 / 170 | 80% | 8.99 | 365 / 459 |
| skin | 94% | 379.30 | 1695 / 1809 | 83% | 9.52 | 394 / 472 |
| bladder | 100% | 263.62 | 21 / 21 | 71% | 7.03 | 360 / 504 |
| esophagus | 95% | 265.92 | 1366 / 1445 | 72% | 5.94 | 131 / 183 |
| adipose | 100% | 1481.55 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 338.38 | 240 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 873.95 | 908 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 87% | 235.99 | 1164 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 71% | 5.32 | 32 / 45 |
| heart | 70% | 140.88 | 607 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 66% | 6.22 | 19 / 29 |
| muscle | 63% | 120.75 | 507 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 14% | 0.94 | 11 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006633 | Biological process | fatty acid biosynthetic process |
| GO_0033306 | Biological process | phytol metabolic process |
| GO_0005778 | Cellular component | peroxisomal membrane |
| GO_0005829 | Cellular component | cytosol |
| GO_0005777 | Cellular component | peroxisome |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0008670 | Molecular function | 2,4-dienoyl-CoA reductase (NADPH) activity |
| GO_0019166 | Molecular function | trans-2-enoyl-CoA reductase (NADPH) activity |
| GO_0005102 | Molecular function | signaling receptor binding |
| Gene name | PECR |
| Protein name | Peroxisomal trans-2-enoyl-CoA reductase (TERP) (EC 1.3.1.38) (2,4-dienoyl-CoA reductase-related protein) (DCR-RP) (HPDHase) (Short chain dehydrogenase/reductase family 29C member 1) (pVI-ARL) Peroxisomal trans-2-enoyl-CoA reductase (EC 1.3.1.38) |
| Synonyms | PRO1004 SDR29C1 |
| Description | FUNCTION: Participates in chain elongation of fatty acids. Catalyzes the reduction of trans-2-enoyl-CoAs of varying chain lengths from 6:1 to 16:1, having maximum activity with 10:1 CoA. Has no 2,4-dienoyl-CoA reductase activity. . FUNCTION: Participates in chain elongation of fatty acids. Catalyzes the reduction of trans-2-enoyl-CoAs of varying chain lengths from 6:1 to 16:1, having maximum activity with 10:1 CoA. Has no 2,4-dienoyl-CoA reductase activity. . |
| Accessions | B4DJS2 Q9BY49 ENST00000442122.5 ENST00000265322.8 [Q9BY49-1] |
